No immediate catalyst; the stock will likely trade on pipeline sentiment until topline data in late Q3/early Q4 2026. Monitor for any safety signals or interim updates.
Price Chart
Executive Summary
Tiziana Life Sciences announced that the last patient in its Phase 2a INFORM-MS trial of intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS) has received their first dose. Topline data is expected in late Q3/early Q4 2026, with a planned presentation at the ACTRIMS-ECTRIMS meeting in October 2026. This is a routine clinical milestone with no financial data or results disclosed.
Key Facts
- Last patient dosed in Phase 2a INFORM-MS trial (NCT06292923) of intranasal foralumab for na-SPMS.
- Topline data expected late Q3/early Q4 2026, with presentation at ACTRIMS-ECTRIMS meeting in October 2026.
- Trial is randomized, double-blind, placebo-controlled, enrolling up to 48 patients across multiple U.S. sites.
- Primary endpoint is change in microglial activation measured by PET scans.
Financial Impact
No financial figures reported; pre-revenue clinical-stage biotech.
Risk Factors
- Clinical trial failure or disappointing topline data could lead to significant downside.
- Pre-revenue company with ongoing cash burn and potential dilution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-071738 |
| Document: ea029591501ex99-1.htm | 0001213900-26-071738 |
| Document: 0001213900-26-071738-index-headers.html | 0001213900-26-071738 |
| Document: 0001213900-26-071738-index.html | 0001213900-26-071738 |
| Document: 0001213900-26-071738.txt | 0001213900-26-071738 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8720 (−13.66%) |
Oct 16, 2026 11d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8720 (+13.66%) |
Oct 16, 2026 11d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8720 (−16.95%) |
Sep 30, 2026 27d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8720 (−21.44%) |
Sep 28, 2026 29d ago | 6-K | $0.9800 $0.8850 | ▼ −9.69% | ▼ −9.66% | $0.8720 (−11.02%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8720 (−3.60%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8720 (−10.10%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8720 (−10.10%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8720 (−24.17%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8720 (−10.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers